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Abstract
Background: Multiple sclerosis (MS) is an autoimmune disease which results from the invasion of the brain by
activated immune cells across the endothelial cells (ECs) of the blood-brain barrier (BBB), due to loss of immune
self-tolerance. Many reports define the metabolic profile of immune cells in MS, however little is known about the
metabolism of the BBB ECs during the disease. We aim to determine whether circulating factors in MS induce
metabolic alterations of the BBB ECs compared to a healthy state, which can be linked with disruption of BBB
integrity and subsequent immune cell extravasation.
Methods and results: In this report, we used an in vitro model to study the effect of sera from naïve-to-treatment,
relapsing-remitting MS (RRMS) patients on the human brain microvascular endothelium, comparing effects to age/
sex-matched healthy donor (HD) sera. Our data show that RRMS serum components affect brain endothelial cells
by impairing intercellular tightness through the down-modulation of occludin and VE-cadherin, and facilitating
immune cell extravasation through upregulation of intercellular adhesion molecules (ICAM-1) and P-glycoprotein (P-
gp). At a metabolic level, the treatment of the endothelial cells with RRMS sera reduced their glycolytic activity
(measured through the extracellular acidification rate-ECAR) and oxygen consumption rate (oxidative
phosphorylation rate-OCR). Such changes were associated with the down-modulation of endothelial glucose
transporter 1 (GLUT-1) expression and by altered mitochondrial membrane potential. Higher level of reactive
oxygen species released from the endothelial cells treated with RRMS sera indicate a pro-inflammatory status of the
cells together with the higher expression of ICAM-1, endothelial cell cytoskeleton perturbation (stress fibres) as well
as disruption of the cytoskeleton signal transduction MSK1/2 and β-catenin phosphorylation.
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Conclusions: Our data suggest that circulating factors present in RRMS patient serum induce physiological and
biochemical alterations to the BBB, namely reducing expression of essential tightness regulators, as well as reduced
engagement of glycolysis and alteration of mitochondrial potential. As these last changes have been linked with
alterations in nutrient usage and metabolic function in immune cells; we propose that the BBB endothelium of MS
patients may similarly undergo metabolic dysregulation, leading to enhanced permeability and increased disease
susceptibility.
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Background
Multiple sclerosis (MS) is the most common chronic in-
flammatory demyelinating disorder of the central ner-
vous system (CNS), mediated by autoimmune T cells
reaching the brain parenchyma and attacking the myelin
sheath [1]. Key features of the disease include blood-
brain barrier (BBB) damage, multifocal inflammation,
demyelination, oligodendrocyte loss, reactive gliosis and
axonal degeneration [2]. Accumulating evidence suggests
a role for metabolic changes in MS; obesity has been
proposed as a risk factor for developing MS, through a
direct crosstalk between energy metabolism alterations
in T lymphocytes and their pro-inflammatory behaviour
[3]. Moreover, studies have shown that some hormones,
including leptin, insulin and ghrelin, play an important
role in the initiation and progression of MS [4]. In this
regard, it seems that MS patients present alterations in
several components of the glycolytic pathway, including
elevated lactate levels [5] in the blood, increased activity
of enolase, pyruvate kinase and aldolase in cerebrospinal
fluid (CSF) [6] accompanied by the presence of anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
autoantibodies in the CSF, leading to downregulation of
glycolytic pathways. Moreover, immuno-metabolic ana-
lysis on naïve -to -treatment RRMS patients has shown
that leptin levels are linked to the severity of disease dis-
ability [7]. Migration of activated T regulatory cells
(Treg) into inflamed tissue is crucial for their immune-
modulatory function [8], this being controlled by distinct
metabolic pathways [3]; impaired glycolysis would con-
sequently affect their migration and/or impact on self-
recognition. In agreement with such findings, we have
recently shown an increased migratory capacity of
CD4+RORgt+ T (TH17) cells from RRMS subjects in an
in vitro model of BBB [9].
Studies to date have mainly centred on the metabolic
status of immune cells, but so far no data have been pro-
vided on the metabolic status of the endothelial cells
(ECs) of the BBB, the interface between the periphery
and the CNS, which shows impaired barrier properties
in MS [10]. The BBB is a complex cellular three-
dimensional structure composed of ECs, pericytes, astro-
cytes end-feet and extracellular matrix which separates
the brain parenchyma from systemic circulation [11].
Far from being inert, the BBB actively controls the trans-
port of molecules and immune cells from blood to brain
parenchyma via the regulation of endothelial junction
organization and expression of specific transporters [12,
13]. The extreme tightness of the microcirculation at
BBB level is due to the presence of specialized endothe-
lial junctional structures called tight junctions (TJ), a
protein complex composed by transmembrane (claudin-
5 and occludin) and cytoplasmic (ZO-1, 2 and 3) pro-
teins with cytoskeleton (actin) [11]. In addition, adherens
junctions (AJ), composed by VE-cadherin and catenins,
also synergise with the TJ in maintaining the barrier
[14]. Moreover, ECs are responsible for providing the
nutrients necessary for brain function by selectively ex-
changing molecules with the blood, a task performed
mainly by active, energy-consuming transporters. Conse-
quently, not only is there a higher metabolic demand on
the ECs of the BBB compared to others in the body, but
any failure in the regulation of cerebral endothelial
metabolic processes can lead to functional BBB alter-
ations. In this study, we have investigated the impact of
circulating factors present in RRMS patients on normal
ECs of the BBB. We show that the endothelial cells
present altered glycolysis and oxidative respiration, simi-
lar to the adaptive cells of the immune system, a change
culminating in perturbed barrier function.
Methods
Cells
As a general in vitro model of the human BBB, we used
hCMEC/D3 cells [15]. hCMEC/D3 were cultured in tis-
sue culture flasks previously coated with 1 μg/ml rat tail
collagen type I solution, in EBM-2 complete medium
(Lonza). Cultures were maintained at 37 °C in 5% CO2,
replaced with fresh medium every 3 days, and split when
they reached 100% confluence.
Samples
Blood samples from RRMS patients (adults, newly diag-
nosed) and healthy donors (HD) were collected follow-
ing the recommendations of Ethical Committees:
Università degli Studi di Napoli “Federico II”. RRMS
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subjects were enrolled by our clinician collaborator at
Universita` degli Studi di Napoli “Federico II”, Azienda
Ospedaliera di Rilievo Nazionale “Antonio Cardarelli”
Napoli (Italy). Peripheral blood was obtained from
RRMS and healthy subjects after they signed a written
informed consent approved by the institutional review
board, as previously described [9, 16].
The study population consisted of 30 subjects, 62.3%
females with an average age of 37.7 ± 12.2 (mean ± s.d.)
years and a body mass index (BMI) of 26.4 ± 5.7 (mean
± s.d.) kg/m2. All RRMS subjects were at diagnosis and
had a Kurtzke Expanded Disability Status Scale (EDSS)
[17] score between 0 and 6, with a median of 2.0 and a
disease duration of 2.4 ± 4.4 (mean ± s.d.) years. Healthy
subjects were matched for age, body mass index (BMI)
and sex and had no recent history of inflammation, nei-
ther endocrine nor autoimmune disease. The ethnic dis-
tribution amongst the groups was comparable with all
participants being Caucasian European.
Serum and plasma were isolated from whole blood by
density gradient centrifugation and stored at −80 °C.
Serum used for all biological tests (transmigration assay,
western blotting and ImageStream) was decomplemen-
ted (20 min at 56 °C) prior to the experiments. Cells
were incubated (16 h) with EBM2 medium containing
20% sera from RRMS patients or matched HD to evalu-
ate the effect of serum components on brain ECs.
hCMEC/D3 cells were grown in 6-well or 24-well plates;
per well sera were pooled from 2 donors (RRMS or
healthy), matching in age, sex and EDSS score. Each well
was treated with different pooled sera pairs. N numbers
in figure legends represent the total number of individ-
ual donor sera used. Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood as previously
reported [9, 16]. Briefly, blood samples were carefully
layered on top of the Ficoll solution (Sigma-Aldrich) and
then centrifuged (2000 RPM, 30min, at room
temperature) to form layers containing different cell
types. After centrifugation, PBMCs were collected in a
whitish layer between the plasma (top) and the erythro-
cyte (bottom) layers. PBMCs were counted, suspended
in FBS solution containing 10% DMSO (Sigma-Aldrich)
and stored in liquid nitrogen.
Transmigration assay
hCMEC/D3 cells were grown (72 h) on Transwell poly-
carbonate filters (membrane diameter 6.5 mm, 5 μm por-
osity—Corning, Germany) previously coated with calf
skin collagen type I (Sigma-Aldrich) and bovine plasma
fibronectin (Sigma-Aldrich). Transmigration assays were
run with PBMCs in their autologous sera (AS) or with a
swap of sera, i.e., healthy donor PBMC + AS or healthy
donor PBMC + RRMS patient sera. EBM-2 complete
medium (w/o VEGF) containing 20% sera was added to
the lower compartment of Transwell 30 min prior
to transmigration assay. Then, PBMCs (1x106 cells) were
suspended in EBM2 medium containing sera and added
to the upper compartment of Transwell in contact with
hCMEC/D3 monolayer. The transmigration assays were
run during 4 h at 37 °C at 5% CO2. Adhered cells were
detached from the top compartment of Transwell by
using a 0.2% trypsin solution, whereas transmigrated
cells were collected from the bottom compartment by
aspirating the medium. Cells were fixed with 2% PFA
(10 min at room temperature), and staining was per-
formed for further FACS analysis on the transmigrated
cells.
FACS analysis
hCMEC/D3 cells incubated (16 h) in EBM2 medium
containing 20% sera from RRMS patients or matched
HD were collected in FACS buffer, fixed with 2% formal-
dehyde (Sigma-Aldrich) for 10 min at RT and washed
with FACS buffer (1% BSA in PBS). ICAM-1 APC (1:100
Bioscience), VCAM-1 Alexa fluor 488 (1:100,
eBioscience), Occludin AF 405 (1:100 eBioscience)
VeCadherin Alexa fluor 488 (1:100, eBioscience) and P-
glycoprotein Alexa fluor 488 (1:100 ebioscience) were
added for 30 min at room temperature. Between each
step, samples were vortexed and centrifuged for 5 min at
4 °C. Finally, cells were suspended in PBS and analysed
by FACS using a LSR-Fortessa (BD Biosciences), with
10,000 events collected on gated cell population.
The expression of markers in PBMCs were measured
on fixed cells incubated with staining buffer (PBS + 2%
BSA). Cell surface staining for CD4-AF648 was carried
out at room temperature for 30 min. After washing, the
cells were permeabilised using the human Foxp3 buffer
set (BD Biosciences) for 20 min followed by a wash step
and staining within intracellular markers Foxp3-PE and
RoRγt-BV421. After a final wash, cells were suspended
in PBS for FACS analysis. All data was analysed using
FlowJo software version 10.
Seahorse metabolic analysis
The metabolic profile of ECs, from healthy and naïve-to-
treatment RRMS subjects, was evaluated through real-
time measurements of extracellular acidification rate
(ECAR) or oxygen consumption rate (OCR), using an
XFe-96 extracellular flux analyzer (Seahorse Bioscience
[18]). ECs were plated in XF-96 plates (Seahorse Bio-
science) at a density of 2 × 104 cells per well and were
cultured in EBM2 medium for 72 h. Sixteen hours prior
to the assay, the medium was changed to EBM2 contain-
ing 20% sera from RRMS patients or matched HD); indi-
vidual donor sera were used per well. ECAR was
measured in XF medium containing 1mM glutamine in
basal conditions and in response to glucose (10 mM),
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Fig. 1 Serum from RRMS patients significantly attenuates BBB function and induces a pro-inflammatory phenotype. Assessment of (a) the trans-
endothelial electrical resistance (TEER) and (b) paracellular permeability of hCMEC/D3 monolayers to 70 kDa FITC-dextran following treatment for
16 h with 20% HD or naïve-to-treatment RRMS sera. c-g Expression of occludin (c), VE-Cadherin (d), ICAM-1 (e), VCAM-1 (f) and P-glycoprotein
(Pgp) (g) in hCMEC/D3 cells treated with HD or RRMS sera. Data are presented as average of three experiments performed on n = 12-24 donors
(pooled in pairs matched in sex, age and EDSS score for RRMS patients), expressed as mean + s.e.m. Statistical analysis are performed by
Student’s t test or by Mann-Whitney U test (two-tails)*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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oligomycin (1 μM) and 2DG (50mM) (all from Sigma-
Aldrich). Metabolic parameters were then calculated
from ECAR profile: basal glycolysis post glucose injec-
tion (after glucose addition), maximal glycolysis (after
oligomycin addition) and glycolytic capacity (calculated
as the difference between oligomycin-induced ECAR
and 2DG-induced ECAR). OCR was measured in XF
medium containing 1 mM sodium pyruvate, 2 mM glu-
tamine and 10 mM glucose in basal conditions and in re-
sponse to oligomycin (1 μM), FCCP (0.5 μM) and
rotenone/antimycin A (0.5 μM each). Metabolic parame-
ters were then calculated from the OCR profile: basal
respiration (without addition of any compound), ATP
production (calculated as the difference between basal
OCR and OCR post oligomycin injection), proton leak
(calculated as the difference between OCR post
oligomycin injection—OCR post-rotenone/antimycin A
injection), maximal respiration (after FCCP addition)
and spare capacity (calculated as the difference between
FCCP-induced OCR and basal respiration). Experiments
with the Seahorse system were done with the following
assay conditions: 3 min of mixture; 3 min of waiting; 3
min of measurement.
Western blot
hCMEC/D3 cells were grown (72 h) on 24-well plates pre-
viously coated with calf skin collagen type I and bovine
plasma fibronectin. Cells were incubated (16 h) with EBM2
medium containing 20% sera from RRMS patients or
matched HD. Following incubation, cells were washed with
cold PBS and cells were suspended in RIPA buffer (1%
Fig. 2 Effect of RRMS sera and matching sex and age HD on PBMCs migration on a normal endothelium. Freshly isolated PBMCs from healthy or
RRMS subjects (n = 6/group) were put in contact for 4 h with hCMEC/D3 monolayer on Transwell polycarbonate filters in the presence of culture
medium supplemented with 20% serum (16 h) from autologous healthy subject (control) or naïve-to-treatment RRMS patient (serum switch
effect) (n = 6 in duplicate). PBMCs from RRMS patients were placed in contact with autologous RRMS patient serum (control) or healthy subject
serum (serum switch effect). a Schematic diagram of experiment. After 4 h, the number of (b) CD4+RoRγt+ (TH17) and (D) CD4+Foxp3+ (Treg)
migrated was evaluated by FACS analysis. Data are expressed as fold increase (% of relative control). Statistical analysis are performed by using
Mann-Whitney U test (two tails) (mean ± s.e.m.); *P ≤ 0.05
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Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150mM
NaCl, and 50mM Tris-HCl, and pH 7.2) supplemented
with protease inhibitors (aprotinin, leupeptin, PMSF, so-
dium fluoride and sodium orthovanadate). Cell lysates were
centrifuged (900 g at 4 °C for 20min) and total protein con-
tent was determined by the BCA method. Samples (10 μg)
were separated by SDS-PAGE (10%), and transferred to a
nitrocellulose membrane in a transfer apparatus (Bio-Rad
Laboratories, CA, USA). Membranes were incubated (1 h at
room temperature) in blocking buffer (TBS-T containing
3% bovine serum albumin), followed by incubation (16 h at
4 °C) with anti-hexokinase-1 (Abcam ab 65069) dilution 1/
800, anti-aldolase (Abcam ab169544) dilution 1/2000,
anti-enolase-1 (Abcam ab155102) dilution 1/2000, anti-
DLAT (Sigma SAB2108113) dilution 1/1000, anti-
aconitase-2 (Abcam ab110321) dilution 1/1000, anti-
DLST (Abcam ab177934) dilution 1/10000 or anti-ERK1/
2 (Cell Signalling Technology #9102) dilution 1/1000.
Membranes were developed using ECLTM (GE Amer-
sham) reagent and immunoreactive bands were detected
by exposure to photographic film. Band intensities were
measured by optical densitometry using the ImageJ (NIH,
USA) software, with ERK1/2 being used as the loading
control.
Confocal microscopy
hCMEC/D3 cells were grown on chambered microscope
slides coated with 0.1 μg/ml calf skin collagen type I
(Sigma-Aldrich) in VEGF-free EBM-2MV medium (Pro-
mocell, UK). Cells were stimulated for 24 h with media
containing 20% sera from RRMS patients or matching
HD (n = 3). Cells were fixed in 2% formaldehyde in PBS
Fig. 3 Confocal analysis of F-actin distribution in hCMEC/D3 cells treated with 20% RRMS or HD sera. hCMEC/D3 cells were treated with 20% FCS,
20% HD sera or 20% RRMS sera for 16 h (n = 3) and F-actin distribution was defined by AlexaFluor 488-conjugated phalloidin alongside DAPI
nuclear counterstain. Scale bar = 10 μm
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at 4 °C, rinsed in PBS and incubated with Alexa Fluor
488-conjugated phalloidin (1:200 dilution; Thermofisher
Scientific, UK) for 20 min. Nuclei were counterstained
with 50 ng/ml DAPI in ddH2O and mounted under
mowiol. Images were captured using an LSM880 con-
focal laser scanning microscope (Carl Zeiss Ltd.,
Cambridge, UK) fitted with 405 and 488 nm lasers and
an × 63 oil immersion objective lens (NA, 1.4 mm,
working distance, 0.17 mm). Images were captured with
the ZEN imaging software (Carl Zeiss Ltd., UK) and
analysed using ImageJ 1.51 h (National Institutes of
Health, USA).
Paracellular permeability and TEER
hCMEC/D3 cells were grown on Transwell polycarbon-
ate filters (pore size, 0.4 μm; Sigma-Aldrich) pre-coated
with calf skin collagen type I (Sigma-Aldrich) and bovine
plasma fibronectin (Sigma-Aldrich). Paracellular perme-
ability of 70 kDa FITC-dextran was assessed after stimu-
lation with 20% sera from RRMS patients or matching
HD [19]. Transendothelial resistance across the mono-
layer was determined using an Endohmeter (World Pre-
cision Instruments). Resistance from coated cell-free
inserts was always subtracted from the resistance ob-
tained in the presence of endothelial cells.
Image stream
hCMEC/D3 cells were grown (72 h) on six-well plates
previously coated with calf skin collagen type I and bo-
vine plasma fibronectin. Cells were incubated (16 h) with
EBM2 medium (LONZA-UK) containing 20% sera from
RRMS patients and matched HD. Following incubation,
cells were washed three times with cold PBS and de-
tached from plates by using 0.2% trypsin. Cells were col-
lected and incubated (30 min at 4 °C) with staining
buffer containing rabbit anti-GLUT-1 antibody (Ther-
moFisher Scientific, UK). Next, cells were washed with
cold PBS, centrifuged, and incubated (30 min at 4 °C)
with staining buffer containing Alexa Fluor 488-
conjugated anti-rabbit secondary antibody (Thermo-
Fisher Scientific, UK). Cells were fixed with 2% formal-
dehyde (10 min at room temperature) and permeabilised
(20 min at room temperature) with staining buffer
containing saponin (2.5 μg/ml). DAPI (4’,6-diamino-2-
phenylindole, 50 ng/ml) was used for nuclear staining.
Imaging flow cytometry was performed on an ImageS-
treamx Mark II operated by the INSPIRE software
(Amnis Corporation). Fluorescence was recorded using
excitation with 488 nm laser for AF488/ANXA1 and
405 nm laser for DAPI; emission was collected using a
480-560 nm filter or with a 420-505 nm filter respect-
ively. Bright-field images of cells were collected simul-
taneously. Samples were run alongside single-stained
and unstained control hCMEC/D3 cells, in order to gate
different cell populations (negative or positive staining).
In each experiment, a template of settings was created
and it was applied to all files. A total of 10,000 events
were collected for each sample, and data were analysed
using the IDEAS Application 6.1 software (Amnis
Corporation).
Nitric oxide measurement
Nitric oxide (NO) production was determined by the
Griess reaction, which measures the content of nitrite
(NO2−), a stable and non-volatile product of NO [20] .
Briefly, hCMEC/D3 cells were grown (72 h) on 96-well
plates previously coated with calf skin collagen type I
and bovine plasma fibronectin. Cells were growth for 48
h with EBM2 medium and further incubated for 16 h
with 20% sera from RRMS patients or HD. The super-
natant was collected and centrifuged (1000 g at 4 °C). A
total of 50 μl/well culture medium was incubated (15
min at room temperature) with Griess reagent (5% phos-
phoric acid containing 1% sulfanilamide and 0.1%
naphthylethylenediamine dihydrochloride). Nitrite levels
were determined by comparing the absorbance at 540
nm with a standard curve generated by NaNO2; mini-
mum sensitivity was 3 μM nitrite.
Mitochondria analysis
Mitochondrial mass was assessed by incubating labelled
ECs with 100 nM of MitoTracker Green FM (Thermo-
Fisher) for 30 min at 37 °C, 5% CO2. Mitochondrial
membrane potential was investigated using TMRE
(ThermoFisher), 1 μM TMRE was incubated with la-
belled PBMCs for 30 min at 37 °C, 5% CO2.
(See figure on previous page.)
Fig. 4 RRMS sera induce impaired engagement of glycolysis in ECs from the BBB. a Kinetic profile of ECAR in hCMEC/D3 cells treated overnight
with 20% HD or RRMS naïve-to-treatment sera. Real time ECAR was measured, under basal conditions and in response to glucose, oligomycin
and 2-DG. Indication of glycolytic pathway activation, calculated from hCMEC/D3 ECAR profile: (b) basal glycolysis, (c) glycolytic capacity and (d)
glycolytic reserve. Data are presented as average of three experiments performed on 25 donors/group, matched in sex, age and EDSS score. Data
are shown as mean ± s.e.m. Statistical analysis was performed by paired Wilcoxon test **P ≤ 0.01, ***P ≤ 0.001). e, f Sera isolated from RRMS
patients downregulate GLUT1 expression on membrane of brain ECs. hCMEC/D3 monolayer plated on 24-well plate were treated (16 h) with sera
isolated from RRMS patients and matched HD. Cells were collected and stained with rabbit anti-GLUT-1 antibody. DAPI was used for nuclear
staining. e Imaging flow cytometry was performed on an ImageStreamx Mark II operated by INSPIRE software (Amnis Corporation). f Data
represent % of mean intensity of fluorescence (MIF) in comparison to sera from matched HD. Statistical analysis was performed using Mann-
Whitney U test (two-tails) *P < 0.05 vs HD, n = 5/group
Sheikh et al. Journal of Neuroinflammation          (2020) 17:153 Page 8 of 19
Fig. 5 (See legend on next page.)
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Mitochondrial ROS was measured using MitoSOX Red
tracer (ThermoFisher), 2 μM MitoSOX was incubated
with labelled hCMEC/D3 cells for 15 min at 37oC, 5%
CO2 in phenol red-free medium, cells were washed with
PBS and medium containing 20% serum from healthy
controls or RRMS patients was added. MitoSOX fluores-
cence was monitored every 5 min for a period of 2 h
using a CLARIOStar fluorescence plate reader (BMG
Labtech, Germany) with excitation and emission wave-
lengths of 510 nm and 580 nm respectively. Rate of
change in fluorescence normalised to individual sample
baseline was then compared. Cells treated with 2.5 μM
rotenone were used as a positive control.
Phospho-proteomics
Relative levels of phosphorylation of 43 kinase phos-
phorylation sites and 2 related total proteins were deter-
mined using the human phospho-kinase array kit (R&D
System, ARY003B) following the manufacturer instruc-
tions. Briefly, hCMEC/D3 cells were grown (72 h) on 6-
well plates previously coated with calf skin collagen type
I and bovine plasma fibronectin. Cells were incubated
(16 h) with EBM2 medium containing 20% sera from
RRMS patients and matched HD. Sera were pooled from
10 donors (4 male, 6 female, EDSS score 1.5-2). Then,
cells were washed with cold PBS, suspended in lysis buf-
fer and protein content was measured by performing a
BCA assay. Nitrocellulose membranes containing spot-
ted capture and control antibodies were incubated (16 h
at 4 °C) with cell lysates (400 μg/sample), followed by in-
cubation with a cocktail of biotinylated detection anti-
bodies. Streptavidin-HRP and chemiluminescent
detection reagents were applied and the signal of each
capture spot was detected by exposure to photographic
film. Spot intensities were measured by optical densi-
tometry using the software Image StudioTM Life (LI-
COR Biosciences), and the signal of reference spot was
used as loading control.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 8.1 program (La Jolla, CA, USA). Data were ana-
lysed using parametric (one-way ANOVA or Student’s t
test as appropriate) or non-parametric (Mann-Whitney)
tests depending on normality distribution (Shapiro-Wil-
cox). For ANOVA, post hoc analysis was performed
using Tukey’s honest significant difference test. Signifi-
cance was established when P value ≤ 0.05
Results
RRMS sera treatment induces a pro-inflammatory
phenotype in hCMEC/D3 cells impairing the functionality
We have previously reported the presence of circulating
immuno-metabolic molecules such as sICAM-1 and lep-
tin in the sera of RRMS patients [7]; in this study, we ex-
amined whether such sera would impact the properties
of the BBB using an in vitro model. Treatment of
hCMEC/D3 immortalised human cerebromicrovascular
endothelial cells overnight with 20% sera from naïve-to-
treatment RRMS patients (Supplementary Table 1), sig-
nificantly reduced trans-endothelial electrical resistance
(TEER) and increased paracellular permeability to a 70
kDa FITC-dextran tracer (Fig. 1a-b) compared to cells
exposed to HD sera. In accordance with these functional
increases in permeability, examination of the key inter-
cellular junction components occludin and VE-cadherin
revealed that treatment with RRMS sera significantly re-
duced their expression when compared with cells ex-
posed to HD sera (Fig. 1c-d). Moreover, treatment with
RRMS sera significantly enhanced endothelial expression
of the adhesion molecules ICAM-1 and VCAM-1 which
permit firm adhesion and transmigration of T cells
(Fig. 1e-f), indicating a switch towards an inflamma-
tory cell phenotype. A central feature of the BBB is
the expression of a wide range of xenobiotic export
transporters, of which P-glycoprotein is perhaps the
most studied [21]. Expression of this transporter was
significantly upregulated by treatment with RRMS
sera (Fig. 1g), a change which may also reflect the in-
flammatory status of the cells as P-glycoprotein is
known to facilitate leukocyte migration into the brain
parenchyma [21].
As well as regulating passage of solutes and molecules
into the brain, the BBB also controls leukocyte migra-
tion, a step particularly important for the immune pro-
tection of the brain. In MS, such control is lost and we
have recently shown that T cells exhibit a pro-migratory
profile in RRMS patients [9]. To specifically investigate
the dual effects of RRMS sera on both the endothelium
and on PBMC, we measured T cell subset migration
across hCMEC/D3 cells pre-treated with the sera of
RRMS patients or HD. The presence of RRMS patient
(See figure on previous page.)
Fig. 5 RRMS sera induce an altered mitochondrial respiration in ECs. a Kinetic profile of OCR in hCMEC/D3 cells treated overnight with 20% HD
or RRMS naïve-to-treatment sera. Real time OCR was measured, under basal conditions and in response to oligomycin, FCCP, Antimycin A and
Rotenone. Indices of mitochondrial respiratory function, calculated from hCMEC/D3 OCR profile: basal and maximal respiration (b, e), ATP
production (c), proton leak (d) and spare capacity (f). Graphics are a cumulative data performed on 10-15 donors/group, matched in sex, age and
EDSS score. Data are shown as mean ± s.e.m. (statistical analysis by Mann-Whitney U test (two-tails)*P ≤ 0.05, **P ≤ 0.01)
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sera induces healthy subject T helper (TH)17 cell migra-
tion (CD4+ RoRγt+) (Fig. 2a) in comparison to similar
cells from MS patients incubated in the presence of
healthy donor serum. In contrast, the presence of the
sera from RRMS patients did not significantly affect the
migration of healthy subject T regulatory (Treg) cells
Fig. 6 Impact of RRMS sera treatment on the mitochondria content and membrane potential in brain ECs. (a, b) Representative flow cytometry
plots and cumulative graphs of mitotracker green staining in hCMEC/D3 cells treated with 20% RRMS sera or HD for 16 h. (c, d) Representative
flow cytometry plots and cumulative graphs of TMRE staining showing membrane potential in hCMEC/D3 treated with RRMS or HD sera. Data
are expressed as mean ± s.e.m. of 30 donors/group (pooled in pairs matched in sex, age and EDSS score for RRMS patients). Statistical analysis by
Mann-Whitney U test (two-tails) **P ≤ 0.01
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(CD4+ Foxp3+) when compared to RRMS patient cells
(Fig. 2b). Such data indicate a role for pro-inflammatory
factors present in RRMS sera [7] affecting TH17 cells but
not Treg cells.
Central to efficient BBB function is the link between
tight junction molecules and the actin cytoskeleton, with
the presence of a cortical network of actin fibres being
required for efficient junction operation [22]. To explore
this aspect, we performed confocal microscopic analysis
of F-actin distribution in hCMEC/D3 cells treated with
20% RRMS or HD sera. Notably, exposure to HD sera
did not affect the primarily cortical arrangement of F-
actin fibres seen in untreated cells, but treatment with
RRMS sera showed a clear alteration in F-actin distribu-
tion, with a marked increase in cytosolic stress fibre ap-
pearance (Fig. 3), suggesting a level of stress upon the
cells.
RRMS sera modifies brain endothelial cell metabolic
profile
Having identified clear signs that brain endothelial cells
exposed to RRMS sera are under stress, we examined
possible explanations for these effects. Key to cellular re-
silience is an efficient energy supply, and both glycolysis
and mitochondrial activity in BBB endothelial cells are
critical for their functional activity [23]. Moreover, im-
pairments in cellular energy reserve/spare capacity have
been related to a range of pathologies affecting high en-
ergetic requirement tissues such as the brain [24]. We
and others have shown T cells of RRMS patients exhibit
lower glycolytic rates than those of healthy subjects [3,
6, 9]; hence, we evaluated whether RRMS sera had a
similar effect on ECs through studying glycolysis via
measurement of the extracellular acidification rate
(ECAR) and oxidative respiration measured via oxygen
consumption rate (OCR). Treatment with RRMS sera
caused lower glycolytic activity compared to treatment
with HD sera (Fig. 4a-d), data which correlated with
lower expression of the glucose uptake transporter
GLUT-1 in RRMS sera treated hCMEC/D3 cells than
those treated with HD sera (Fig. 4e-f).
Having identified changes in glycolytic rate induced by
exposure to RRMS sera, we examined whether the other
principal cellular energy pathway, mitochondrial oxida-
tive respiration, would be similarly affected. Compared
with hCMEC/D3 cells treated with 20% HD sera, RRMS
sera significantly reduced maximal oxygen consumption
(Fig. 5e) revealing a loss in spare capacity (Fig. 5f), an es-
timate of the potential bioenergetic reserve the cell can
call upon, without affecting ATP production rates or
proton leakage (Fig. 5b-d).
RRMS sera impairs brain endothelial cell mitochondrial
function
The mitochondria are the main site of oxygen con-
sumption in a cell; hence, we examined their struc-
tural and functional integrity in response to RRMS
sera. Using MitoTracker Green, a mitochondrial-
specific dye that binds to mitochondrial membrane
independently of mitochondrial membrane potential,
we found no difference in mitochondrial mass be-
tween ECs treated with RRMS or HD sera (Fig. 6a
and the histogram).
Fig. 7 RRMS sera stimulate ROS production in ECs of BBB. a ECs were preloaded with 2 μM Mitosox red, then incubated for 2 h at 37 °C,
fluorescence measured every 5 min and rate of fluorescence increase determined. ECs were either untreated (EBM-2MV medium only), stimulated
with 2.5 μM rotenone (mitochondrial complex I inhibitor; positive control), or treated with 20% human serum in EBM-2MV medium. Data are
mean ± s.e.m., n = 7 for untreated and rotenone, n = 10 for HC or RRMS samples. Data analysed by one-way ANOVA with Tukey’s HSD post hoc
test. p = 0.014 RRMS vs HD, p = 0.011 vs untreated. b NO production in hCMEC/D3 cells treated overnight with 20% serum from RRMS naïve-to-
treatment or HD, determined by Griess assay. Data are expressed as mean + s.e.m. of duplicates, one representative from three independent
experiments (n = 5-8 donors/group), (Mann-Whitney U test (two-tails)*P ≤ 0.05
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As the mitochondrial membrane potential (Ψm) gener-
ated by proton pumps (complexes I, III and IV) is essential
for energy mobilisation during oxidative phosphorylation
[20], we investigated how brain endothelial cell Ψm was
affected by incubation with RRMS sera using the tracer
TMRE. ECs exposed to 20% RRMS sera had a significantly
higher proportion of hyperpolarised mitochondria than
cells treated with HD sera (Fig. 6c-d). Hyperpolarised
mitochondria can be a source of reactive oxygen species
(ROS), which can potentially cause cellular damage [25];
hence, we examined the impact of RRMS sera exposure
upon hCMEC/D3 cells. Mitochondrial superoxide produc-
tion, measured using MitoSOX Red, was found to be sig-
nificantly higher in ECs treated with RRMS sera, whilst no
differences were found between untreated and HD sera
treated ECs (Fig. 7a). Similarly, production of nitric oxide
(NO-measured through analysis of its stable metabolite,
nitrite) was significantly greater in ECs treated with RRMS
sera than those exposed to HD sera (Fig. 7b).
Signalling behind the effect of RRMS sera on ECs change
To interrogate the alterations in glycolysis (ECAR) and
oxidative respiration (OCR) described above, we investi-
gated expression of key glycolytic and Kreb’s cycle en-
zymes in hCMEC/D3 cells treated for 16 h with 20%
RRMS or HD sera. Analysis of glycolytic enzymes re-
vealed a marked and specific reduction in enolase-1 ex-
pression upon RRMS sera exposure, an effect not seen
for hexokinase or aldolase (Fig. 8a, b), accompanied by
significant increases in expression of the Kreb’s cycle en-
zymes DLST and DALT (Fig. 8c, d).
Microvascular integrity is dependent on tight and
adherens junction assembly which is closely related with
a correct cytoskeleton organization [26]. Additionally,
there is extensive evidence for the interaction of meta-
bolic enzymes with eukaryotic cytoskeleton [27].
To examine the possible signalling cascade coordinat-
ing disrupted metabolism, cytoskeletal remodelling and
endothelial cell junction assembly, we performed
phospho-proteomic analysis of hCMEC/D3 cells treated
with either 20% RRMS or HD sera. Activation of a num-
ber of signalling molecules was detected (Fig. 9a),
amongst which the most significant were p38α, MSK1/2,
β-catenin, FGR, PLCγ1, STAT3 and c-JUN (Fig. 9a, b).
Notably amongst these, the tyrosine kinase FGR has
been shown to regulate cellular fuel choice, permitting
cells to respond to energy depletion [28] and β-catenin
is well known to be required for maintaining adult
blood-brain barrier integrity and CNS homeostasis [28].
Using Enrichr [29, 30] to examine KEGG pathways asso-
ciated with the list of proteins phosphorylated after
RRMS serum exposure, we identified significant over-
representation of several inflammation-related pathways
(Fig. 9c), supporting our previous identification of a pro-
inflammatory EC phenotype.
Together, these data support our hypothesis that fac-
tors present in the serum of RRMS patients can exert a
detrimental impact upon brain EC physiology, reducing
their energy reserves and placing them in a condition of
metabolic stress, effects which contribute to a deterior-
ation in their key physiological role, provision of an ef-
fective permeability barrier. These changes correlate
with a clear appearance of a pro-inflammatory pheno-
type, and facilitate immune cell binding and extravasa-
tion, directly contributing to the progression of MS
disease.
Discussion
The pathogenesis of MS is still unknown but several cellu-
lar mechanisms have been proposed, including genetic
factors, viral infections, autoimmune attack, demyelin-
ation, mitochondrial dysfunction, free radical production,
ionic imbalance and cellular clearance system dysfunction
[31–33]. While all these contribute to the demyelinating
and neurodegenerative characteristics of the disease [34],
one of the established trademarks is the presence of pro-
found abnormalities in the cerebral ECs [35]. These ultim-
ately result in the alteration of normal BBB function,
permitting transendothelial migration of activated leuko-
cytes into the CNS, where they drive inflammation and ul-
timately lead to neurodegeneration [36].
Accumulating evidence suggests that changes in the
metabolism of immune cells, such as normal metabolic
pathway alteration and loss of key metabolites, contrib-
utes to the pathogenesis of autoimmunity, resulting in a
loss of immune tolerance to self [36]. Indeed, it was re-
cently demonstrated that T cells from naïve-to-treat-
ment RRMS patients displayed impaired engagement of
glycolysis and mitochondrial metabolism upon T cell re-
ceptor (TCR) activation, associated with an impaired
(See figure on previous page.)
Fig. 8 Biochemical pathways of brain ECs treated with RRMS sera and matched HD. a Immunoblot for hexokinase, aldolase and enolase-1 on
hCMEC/D3 cells treated overnight with 20% HD or RRMS naïve-to-treatment sera. Total ERK 1/2 served as a loading control. One representative
out of at least three independent experiments performed on 12 donors in total/group. b Densitometry quantification for hexokinase, aldolase
and enolase-1 performed on all 10 donors in total/group. c Immunoblot for DLST and DLAT, on hCMEC/D3 cells treated overnight with 20% HD
or RRMS naïve-to-treatment sera. Total ERK 1/2 served as a loading control. One representative out of at least three independent experiments
performed on 12 donors in total/group. d Densitometry quantification of DLST and DLAT normalized on total ERK 1/2 performed on all 10
donors. Data are expressed as mean ± s.e.m. (statistical analysis by Mann-Whitney U test (two-tails) *P ≤ 0.05)
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generation of Treg cells and a consequent loss of im-
mune self-tolerance [3, 6]. Furthermore, the presence
of higher levels of pro-inflammatory factors, such as
leptin, sCD40L, MCP-1, IL-6 and sTNF-R [7] in
RRMS sera and the specific link with metabolic
alterations in the immune system of MS patients sug-
gests MS can be considered a chronic metabolic dis-
order [37].
The aim of the current work was to verify whether cir-
culating factors found in MS patients [7] affect BBB
structure, function and metabolism. Using the estab-
lished hCMEC/D3 in vitro model of the human BBB
[38], we show for the first time, to our knowledge, that
RRMS serum factors significantly impair BBB integrity,
promote a pro-inflammatory cellular phenotype, and
markedly weaken the ability of the endothelial cells to
maintain an adequate energy supply.
Brain microvascular ECs, being the first contact with
the circulation, possess highly organized tight and adhe-
rens junctions, in order to maintain the restrictive prop-
erties of the BBB. In MS, the presence of pro-
inflammatory factors, activated immunocompetent cells
and reactive nitrogen species result in modifications to
the integrity and organization of these junctional mole-
cules (occludin and claudin and Ve-Cadherin) and con-
sequently enhanced BBB permeability [15]. We show
(See figure on previous page.)
Fig. 9 Phospho-protein activation. a The map display the expression of differentially expressed proteins identified from the proteomics analysis in
hCMEC/D3 cells treated overnight with 20% RRMS naïve-to-treatment or HD sera performed on 10 donors pooled per group pooled (in sex, age
and EDSS score for RRMS patients), in duplicate. The colour scale illustrates the expression level of each protein across the 2 samples; the colour
intensity indicates the degree of protein up- or downregulation. b Average pixel density of phosphorylated proteins known to be involved in
pro-inflammatory processes/pathways significantly different. c Association of all significantly phosphorylated enzymes with KEGG pathways,
ranked in order of p value, Enrichr. Data are shown as mean ± s.e.m. (statistical analysis by Mann-Whitney U test (two tails) *P ≤ 0.05, **P ≤ 0.01
Fig. 10 Schematic diagram. Schematic representation of potential-triggered signals in RRMS patients responsible for the alteration in function
and biochemistry of the ECs of the BBB. Pro-inflammatory mediators circulating in RRMS patients will affect the essential components of the BBB
ECs named occludin, VE-cadherin as well as P-glycoprotein (P-gp). Adhesion molecules are also upregulated facilitating the adhesion and
transmigration trough disruption of tight and adherens junctions. RRMS sera factor (pro-inflammatory and endocrine such as leptin) will also
impact on the ECs metabolism down modulating the GLUT-1 receptor and triggering an impaired glucose (ECAR) and oxidative respiration (OCR)
damaging the mitochondria and prompting the release of reactive species (ROS) which will further disrupt the neurovascular unit (basal lamina
and astrocytes end-feet) targeting the neurons in the brain parenchyma
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here that the sera from naïve-to-treatment RRMS pa-
tients induced alterations to BBB permeability and regu-
lated essential mediators of the tightness of the BBB
(occludin and VE-cadherin). These effects were most
probably mediated by the presence of circulating factors
in RRMS serum, known to include pro-inflammatory cy-
tokines such as IL-6 and CD40L, as described previousl
y[7]. Moreover, this milieu upregulates adhesion mole-
cules, such as ICAM-1, favouring the firm adhesion of
leukocytes and their transmigration into the brain paren-
chyma. Another molecule involved in T cell trafficking
is P-gp, an efflux pump that actively removes toxic com-
pounds from the brain at the cost of ATP hydrolysis
[21], which has also been shown to regulate CD4+ and
CD8+ T cell migration into the brain through release of
CCL2 [21]. In agreement with this, we have shown an
increase in P-glycoprotein expression upon treatment
with RRMS serum. Together, the data we present in this
study strongly indicate the induction of a pro-
inflammatory endothelial phenotype by RRMS serum,
emphasising the presence of pro-inflammatory factors in
the circulation of MS patients.
Interestingly, the functional ECAR/OCR results seen
in ECs post-RRMS serum exposure resemble the
immuno-metabolic profiles of T cells from RRMS pa-
tients [6], namely presenting impaired glycolysis and re-
duced expression of the transporter GLUT-1. These
effects may be caused by the pro-inflammatory mole-
cules present in the sera of patients affected by MS [5].
At the mitochondrial level, hCMEC/D3 cells treated
with RRMS sera displayed a reduction in maximal res-
piration and spare respiratory capacity, further suggest-
ing the inability of the cells to respond to an energetic
demand. Nonetheless, while at a biochemical level, we
found an increase in Kreb’s cycle enzyme expression;
this did not translate into changes in ATP production.
This may reflect an attempt by the cells to try to com-
pensate for the impaired glycolytic function by enhan-
cing Kreb’s cycle activity, or synthesizing other
intermediates for cytokines.
Our data indicate that RRMS serum factors place endo-
thelial cells under energetic stress, with a marked reduc-
tion in glycolytic reserve and mitochondrial spare
capacity, accompanied by a notable loss of mitochondrial
membrane potential. This strongly indicates that the cells
have less resilience to challenge, such as inflammation.
Importantly, depletion of reserve respiratory capacity
through mitochondrial dysfunction has been shown to
underlie increased BBB permeability in animal models of
occlusive stroke and endotoxaemia [39]. This idea is
strongly supported by our findings that whilst mito-
chondrial mass was unchanged by RRMS sera expos-
ure, clear signs of mitochondrial dysfunction are
present, including mitochondrial membrane
hyperpolarisation and a loss in basal and maximal
respiration rate and respiratory spare capacity. Simi-
larly, the increase in mitochondrial membrane poten-
tial identified by increased TMRE accumulation also
indicates a degree of mitochondrial stress, as sug-
gested by increased superoxide and nitric oxide pro-
duction, leading to activation of signaling pathways
driving changes in energy metabolism.
The changes we have seen in the endothelial cells
may have consequences for the other members of
the neurovascular unit. We have studied an in vitro
model of endothelial cells in isolation, whereas in the
true BBB, the function of these cells is supported
and regulated by the other cell types, especially peri-
cytes and astrocytes [38]. Production of high levels of
ROS and nitric oxide by endothelial cells operating
under conditions of metabolic stress may well be
harmful for these other cell types, further weakening
BBB properties.
Conclusions
Our data show that the endothelial cells of the BBB ex-
posed to circulating factors present in the sera of RRMS
patients undergo a perturbation of mitochondrial func-
tion and oxidative respiration, associated with cytoskel-
etal dysfunction, enhanced barrier permeability and
induction of a pro-inflammatory phenotype. We propose
(see scheme Fig. 10) that in MS the BBB disruption may
be secondary to circulating immune factors which are
primary to the chain of events contributing to the dis-
ease. Dampening inflammation and controlling endo-
crine factors may help repair the BBB damage with a
beneficial effect on disease control and progression.
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